Treatment of Bipolar Disorders and Metabolic Syndrome: Implications for Primary Care

References

• . Kessler R, Stafford D. Primary care is the de facto mental health system. In: Kessler R, Stafford D, eds. Collaborative Medicine Case Studies. New York, NY; Springer 2008:9–21
   Google Scholar
• . Lieberman JA. The use of antipsychotics in primary care. Primary Care Companion Journal of Clinical Psychiatry. 2003;5( suppl 3):3–8
   Google Scholar
• . US Preventive Services Task Force. Screening for depression: recommendations and rationale. Am Fam Physician. 2002;66(4):647–650
   PubMed Web of Science ®Google Scholar
• . Manning JS. Bipolar disorder in primary care. J Fam Pract. 2003( suppl): S6–S9
   Google Scholar
• . Tohen M, Angst J. Epidemiology of bipolar disorder. In: Tsuang MT, Tohen M, eds. Textbook in Psychiatric Epidemiology. 2nd ed. New York, NY: John Wiley and Sons; 2002:427–444
   Google Scholar
• . Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161–174
   PubMed Web of Science ®Google Scholar
• . Citrome L, Goldberg JF. Commentary: bipolar disorder is potentially fatal. Postgrad Med. 2005;117(2):9–11
   PubMed Web of Science ®Google Scholar
• . American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Text Revision. Washington DC: American Psychiatric Association; 1994
   Google Scholar
• . Judd LL, Akiskal HS, Schettler PJ, . The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–537
   PubMed Web of Science ®Google Scholar
• . Judd LL, Akiskal HS, Schettler PJ, . A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261–269
   PubMed Web of Science ®Google Scholar
• . Citrome L, Goldberg JF. The many faces of bipolar disorder. How to tell them apart. Postgrad Med. 2005;117(2):15–16
   PubMed Web of Science ®Google Scholar
• . Cusack JR. Bipolar disorder: How to recognize and treat in primary care. Consultant. 2002;42:912–926
   Google Scholar
• . Marken PA, Pies RW. Emerging treatment for bipolar disorder: safety and adverse effects profiles. Ann Pharmacother. 2006;40(2):276–285
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601
   PubMed Web of Science ®Google Scholar
• . Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68( suppl 1):20–27
   PubMed Web of Science ®Google Scholar
• . Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with the use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol. 2006;164(7):672–681
   PubMed Web of Science ®Google Scholar
• . Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64(12):1426–1435
   PubMed Web of Science ®Google Scholar
• . Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812–819
   PubMed Web of Science ®Google Scholar
• . Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;(1):CD003041
   Google Scholar
• . Krishnan KR. Psychiatric and medical comorbidity of bipolar disorder. Psychosomatic Med. 2005;67:1–8
   PubMed Web of Science ®Google Scholar
• . McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17(2):83–93
   PubMedGoogle Scholar
• . Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293(2):2528–2530
   PubMedGoogle Scholar
• . The American Heart Association and the National Heart, Lung, and Blood Institute. 2008. http://www.americanheart.org/presenter.jhtml?identifier=4756. Accessed December 2008
   Google Scholar
• . Narasimhan M, Bailey SB. Schizophrenia, metabolic syndrome, and antipsychotics challenges, controversies, and clinical management. Psychiatric Times. March 2008. http://www.psychiatrictimes.com/schizophrenia/article/10168/1147401. Accessed December 2008
   Google Scholar
• . Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161(9):1709–1711
   PubMed Web of Science ®Google Scholar
• . Koro CE, Fedder DO, L'Italien GJ, . An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59(11):1021–1026
   PubMed Web of Science ®Google Scholar
• . Brixner DI, Said Q, Corey-Lisle PK, . Naturalistic impact of second generation antipsychotics on weight gain. Ann Pharmacother. 2006;40(4):626–632
   PubMed Web of Science ®Google Scholar
• . Mallya A, Chawla P, Boyer SK, DeRosear L. Resolution of hyperglycemia on risperidone discontinuation: a case report. J Clin Psychiatry. 2002;63(5):453–454
   PubMed Web of Science ®Google Scholar
• . Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with resperidone treatment? Psychosomatics. 2000;41(4):369–370
   PubMed Web of Science ®Google Scholar
• . Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62( suppl 23):30–38
   PubMed Web of Science ®Google Scholar
• . Haupt DW, Newcomer JW. Risperidone-associated diabetic ketoacidosis. Psychosomatics. 2001;42(3):279–280
   PubMed Web of Science ®Google Scholar
• . Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated new-onset diabetes. Biol Psychiatry. 2001;50(2):148–149
   PubMed Web of Science ®Google Scholar
• . Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol. 2004;24(5 suppl 1):S1–S6
   PubMedGoogle Scholar
• . Barnett AH, Mackin P, Chaudhry I, . Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity, and dyslipidaemia. J Psychopharmacol. 2007;21(4):357–373
   PubMed Web of Science ®Google Scholar
• . Lipkovich I, Citrome L, Perlis R, . Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26(3):316–320
   PubMed Web of Science ®Google Scholar
• . Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Psychotherapy, Theory, Research, and Practice. 1982;19:161–173
   Web of Science ®Google Scholar
• . Vallis M, Ruggiero L, Greene G, . Tages of change for healthy eating in diabetes: relation to demographic, eating-related, health care utilization, and psychosocial factors. Diabetes Care. 2003;26(5):1468–1474
   PubMed Web of Science ®Google Scholar
• . Rollnick S, Miller WR. What is motivational interviewing? Behav Cogn Psychother. 1995;23:325–334
   Google Scholar
• . Welch G, Rose G, Ernst MA. Motivational interviewing and diabetes: what is it, how is it used, and does it work? Diabetes Spectrum. 2006;19:5–11
   Google Scholar